Advancing Tinnitus Detection & Research
The TIDE consortium brings together leading researchers to develop innovative approaches for tinnitus detection, diagnosis, and treatment.
The TIDE consortium brings together leading researchers to develop innovative approaches for tinnitus detection, diagnosis, and treatment.
The overarching goal of the Tinnitus Detection (TIDE) consortium is funded by the Rainwater Charitable Foundation and aims to develop an objective method for diagnosing tinnitus. Through the integration of multiple brain activity measurement techniques and artificial intelligence–driven analysis, our goal is to identify a biomarker capable of determining the presence and severity of tinnitus perception.
Developing a biomarker for tinnitus would be both groundbreaking and transformative, advancing patient management to a new level. By deriving two test paradigms from recent tinnitus models and applying them broadly to explain not only its onset but also its wider manifestations, we aim to identify an objective marker—or at least a subtype-specific one—linked to distinct pathophysiology. Such a marker could have major impact and meet the urgent need of the pharmaceutical and hearing tech industries for reliable biomarkers to drive investment in tinnitus research.
Develop a biomarker for tinnitus, create standardized assessment protocols, and establish a global tinnitus research database.
Bringing together audiologists, neuroscientists, clinicians, and engineers.
Translating research findings into clinical applications and personalized treatment approaches.
The TIDE consortium brings together leading experts in audiology, neuroscience, and clinical research.
